考帕松对复发型多发性硬化症中MRI监测的疾病的疗效具有可重复性且持久。
Copaxone's effect on MRI-monitored disease in relapsing MS is reproducible and sustained.
作者信息
Wolinsky J S, Comi G, Filippi M, Ladkani D, Kadosh S, Shifroni G
机构信息
The University of Texas Health Science Center at Houston, 6431 Fannin Street, Houston, TX 77030, USA.
出版信息
Neurology. 2002 Oct 22;59(8):1284-6. doi: 10.1212/wnl.59.8.1284.
All but 6% of the subjects with relapsing remitting MS who were randomly assigned to receive glatiramer acetate or placebo for the 9-month controlled phase of the European/Canadian MRI trial entered an open-label extension with quarterly clinical and MRI evaluations for another 9 months. There was a 54% reduction in the mean number of enhanced lesions for those converted from placebo to glatiramer acetate and an additional 24.6% reduction for those always on glatiramer acetate. Over the entire study the accumulated T2 disease burden was 34.2% less for those always on glatiramer acetate.
在欧洲/加拿大MRI试验为期9个月的对照阶段，所有被随机分配接受醋酸格拉替雷或安慰剂治疗的复发缓解型多发性硬化症受试者中，除6%外，其余均进入开放标签扩展阶段，每季度进行临床和MRI评估，为期9个月。从安慰剂转换为醋酸格拉替雷的患者，强化病灶平均数量减少了54%，而一直使用醋酸格拉替雷的患者又额外减少了24.6%。在整个研究中，一直使用醋酸格拉替雷的患者累积T2疾病负担减少了34.2%。
Zotero 插件